Overview

CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse

Status:
Completed
Trial end date:
1999-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating older patients who have acute myeloid leukemia that has recurred for the first time following at least 3 months of complete remission.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Gemtuzumab